Perseus

Founded in 1995, Perseus is a private equity firm specializing in middle market buyouts, industry consolidations, and growth equity investments. It focuses on companies engaged in content-based technology, biotechnology, healthcare, consumer products, business services, energy, environmental technologies, and highly engineered processes industries. Perseus typically seeks majority ownership and board seats in its portfolio companies.

Norman Selby

Managing Director

25 past transactions

BlueWillow Biologics

Series C in 2012
BlueWillow Biologics, Inc. is a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, specializing in the development of intranasal vaccines and anti-infective products utilizing patented nanotechnology. Founded as a spin-off from the University of Michigan in 1999, the company focuses on creating vaccines that provide mucosal immunity against respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, HSV2, chlamydia, and HIV. Its innovative NanoStat vaccine technology features an oil-in-water nanoemulsion that effectively incorporates and delivers multiple antigens while enhancing immune responses. In addition to its vaccine portfolio, BlueWillow Biologics offers NanoBio Protect, a nasal antiseptic solution. The company has established partnerships, including a licensing agreement with Merck for its adjuvant technology and a strategic alliance with Public Health England to further its mission in combating infectious diseases.

Metamark Genetics

Series B in 2010
Metamark Genetics, founded in 2007, is a life science company focused on developing prognostic and predictive diagnostic tests for cancer patients. The company's core technology, Prognosis Determinants™ Platform, is based on pioneering research by Dr. Lynda Chin at Dana-Farber Cancer Institute and Harvard Medical School. This platform identifies functionally validated genetic elements that drive cancer progression across various types, enabling personalized treatment planning, improved patient outcomes, and reduced healthcare costs. Metamark's advanced proteomics platform specifically addresses the diagnostic and therapeutic journey of prostate cancer patients, offering high sensitivity and accuracy, early-stage disease risk prediction, and automated, digitalized tissue analysis independent of subjective interpretations. This empowers patients and physicians to make informed treatment decisions that enhance quality of life and lower healthcare costs.

CeNeRx BioPharma

Series C in 2010
CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

Cymbet Corporation

Series C in 2010
Cymbet designs and manufactures eco-friendly, biocompatible rechargeable solid-state batteries for microelectronic systems. Its products serve industries such as medical, sensor, RFID, industrial control, communications, and portable electronics. Cymbet offers bare dies, power management/real-time clocks, evaluation kits, and sells through global distributors.

Lumexis

Venture Round in 2009
Lumexis Corporation, founded in 2003 and based in Costa Mesa, California, specializes in the development, manufacturing, and marketing of fiber-to-the-screen (FTTS) in-flight entertainment (IFE) and communication systems. The company's innovative FTTS technology offers a lighter alternative to traditional embedded IFE systems, enhancing system reliability and reducing maintenance costs. Lumexis's solutions enable passengers to engage with multiple screens simultaneously at their seats while enjoying high-definition content on its advanced monitors. In addition to its core products, Lumexis provides customer support, training, and software services to ensure a comprehensive experience for its clients.

BlueWillow Biologics

Series B in 2009
BlueWillow Biologics, Inc. is a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, specializing in the development of intranasal vaccines and anti-infective products utilizing patented nanotechnology. Founded as a spin-off from the University of Michigan in 1999, the company focuses on creating vaccines that provide mucosal immunity against respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, HSV2, chlamydia, and HIV. Its innovative NanoStat vaccine technology features an oil-in-water nanoemulsion that effectively incorporates and delivers multiple antigens while enhancing immune responses. In addition to its vaccine portfolio, BlueWillow Biologics offers NanoBio Protect, a nasal antiseptic solution. The company has established partnerships, including a licensing agreement with Merck for its adjuvant technology and a strategic alliance with Public Health England to further its mission in combating infectious diseases.

BlueWillow Biologics

Series B in 2009
BlueWillow Biologics, Inc. is a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, specializing in the development of intranasal vaccines and anti-infective products utilizing patented nanotechnology. Founded as a spin-off from the University of Michigan in 1999, the company focuses on creating vaccines that provide mucosal immunity against respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, HSV2, chlamydia, and HIV. Its innovative NanoStat vaccine technology features an oil-in-water nanoemulsion that effectively incorporates and delivers multiple antigens while enhancing immune responses. In addition to its vaccine portfolio, BlueWillow Biologics offers NanoBio Protect, a nasal antiseptic solution. The company has established partnerships, including a licensing agreement with Merck for its adjuvant technology and a strategic alliance with Public Health England to further its mission in combating infectious diseases.

SoftSwitching Technologies

Series E in 2008
SoftSwitching Technologies specializes in power quality and monitoring solutions tailored for industries such as semiconductor, food, beverage, and automotive. The company provides a comprehensive range of products, including battery-free DySC systems, intelligent I-Sense sensors that accurately detect and measure the duration of voltage sags, and a unique global notification network called Grid Alert, which reports power events. These products are designed to identify and rectify brief power disruptions, enhancing operational uptime and efficiency in manufacturing processes. By offering affordable and scalable solutions, SoftSwitching Technologies aims to improve power management for its clients across various sectors.

Vehicle Production Group

Private Equity Round in 2008
VPG is working with General Motors through its on-highway integrator Powertrain Integration LLC. Marketing, technical, and infra-structure logistical support for the CNG model will be provided by Clean Energy Fuels Corp., founded by T. Boone Pickens, both of whom are also investors in VPG. The vehicle will be assembled by AM General LLC, in Mishawaka, Indiana, and will employ a classic front-engine, rear-wheel drive architecture which includes a durable body-on-frame structure. Vehicle access is compliant with the vehicle requirements of the Americans with Disabilities Act ("ADA"). The vehicle includes an integrated automatic ramp that will provide quick and easy access for individuals who use wheelchairs, motorized scooters and other mobility devices. Originally introduced as the "Standard Taxi", VPG's vehicle has undergone design and functional enhancements based on input from the marketplace.

Bioenvision

Venture Round in 2007
Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.

Ascenta Therapeutics

Series C in 2007
Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

Map Pharmaceuticals

Series D in 2007
Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.

Serveron

Series G in 2007
Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

BlueWillow Biologics

Series A in 2006
BlueWillow Biologics, Inc. is a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, specializing in the development of intranasal vaccines and anti-infective products utilizing patented nanotechnology. Founded as a spin-off from the University of Michigan in 1999, the company focuses on creating vaccines that provide mucosal immunity against respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, HSV2, chlamydia, and HIV. Its innovative NanoStat vaccine technology features an oil-in-water nanoemulsion that effectively incorporates and delivers multiple antigens while enhancing immune responses. In addition to its vaccine portfolio, BlueWillow Biologics offers NanoBio Protect, a nasal antiseptic solution. The company has established partnerships, including a licensing agreement with Merck for its adjuvant technology and a strategic alliance with Public Health England to further its mission in combating infectious diseases.

Map Pharmaceuticals

Series C in 2006
Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.

Serveron

Series F in 2006
Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

Iridian Technologies

Series C in 2005
Iridian Technologies, founded in 1990 and headquartered in Moorestown, New Jersey, specializes in the research, development, and marketing of biometric identifiers. The company offers PrivateID, an image processing protocol enabling secure iris recognition, and KnoWho, an authentication server for identity verification. Their products cater to public-use applications like border control and restricted access systems, distributed through integrators and application partners. Prior to its acquisition by Viisage Technology Inc. in 2006, the company operated under the name IriScan, Inc., changing its moniker to Iridian Technologies in 2000.

Serveron

Venture Round in 2004
Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

Serveron

Venture Round in 2003
Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

Evergreen Solar

Post in 2003
Evergreen Solar, Inc. is a developer and manufacturer of solar power products that utilizes its proprietary STRING RIBBON™ technology, which allows for the production of photovoltaic modules with significantly reduced polysilicon usage compared to traditional methods. The company focuses on delivering reliable and environmentally friendly electric power solutions for both residential and commercial applications worldwide. By leveraging its patented wafer manufacturing technology, Evergreen Solar aims to lower production costs through reduced material consumption and efficient processes, enabling broader access to solar energy. Its products are designed for deployment in various markets, including remote and grid-connected environments, facilitating the harnessing of solar power for diverse energy needs.

SoftSwitching Technologies

Series C in 2002
SoftSwitching Technologies specializes in power quality and monitoring solutions tailored for industries such as semiconductor, food, beverage, and automotive. The company provides a comprehensive range of products, including battery-free DySC systems, intelligent I-Sense sensors that accurately detect and measure the duration of voltage sags, and a unique global notification network called Grid Alert, which reports power events. These products are designed to identify and rectify brief power disruptions, enhancing operational uptime and efficiency in manufacturing processes. By offering affordable and scalable solutions, SoftSwitching Technologies aims to improve power management for its clients across various sectors.

Encorp

Series D in 2001
Encorp specializes in distributed energy management. It offers advanced software and hardware solutions that integrate diverse power resources like engine-generator sets, microturbines, fuel cells, CHP systems, and energy storage devices. These technologies enhance energy efficiency, reliability, and cost-effectiveness for commercial, institutional, and federal installations.

Biometric Access

Series B in 2001
Biometric Access Company (BAC) provides innovative yet practical system solutions that improve data management and transaction processing. Optional ID verification is available through our advanced biometric technologies. BAC is committed to price/performance leadership and the development of superior hardware, software and total system solutions that offer an outstanding return on investment to our customers. As the sole proprietor of our SecureTouch® products, BAC designs, develops, manufactures and markets several hardware and software applications to provide complete user solutions.

Serveron

Venture Round in 2001
Serveron Corporation specializes in developing and supporting online transformer products and diagnostic services. The company provides transformer monitors that deliver essential asset data, including dissolved gas analysis of insulating oil in power transformers and other oil-filled equipment. Its offerings also include monitoring services that allow users to access data from any internet-connected Windows PC, transformer bushing monitors for power factor testing, and advisory services to help utilities manage their transformer fleets. Additionally, Serveron focuses on energy asset management, enabling real-time monitoring, control, and reporting of remote energy systems. The company serves utilities, industrial users, and service organizations both in the United States and internationally. Headquartered in Hillsboro, Oregon, Serveron Corporation operates as a subsidiary of BPL Global, Ltd.

ClubMom

Series B in 2000
Founded in 1999, ClubMom is a national membership organization dedicated to supporting mothers. It offers an online platform where members can engage in discussions about topics relevant to them, providing answers, support, and insights to help manage their busy lives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.